Teva to acquire Allergan’s generics unit for $40.5 billion in cash and stock
On Monday, Teva Pharmaceutical Industries Ltd. said that it would acquire generics unit of Allergan for $40.5 billion in cash and stock.
Biogen’s Alzheimer’s Drug reports lackluster results
Biogen Inc's experimental Alzheimer's drug gave disappointing results at an international conference. Shares of the Cambridge company fell 4.34% to $391.74 yesterday after the results were declared.
Gilead Sciences declines to $115.13 per Share
Gilead Sciences stock declined in the last trading session to $115.1. The stock has been recently under pressure as investors feel that the company has been overvalued.
Vitae-Boehringer diabetes drug not successful as add-on therapy in trials
According to Vitae Pharmaceuticals Inc, its diabetes drug was not able to considerably reduce blood sugar levels of patients when it was used as an add-on therapy.
Bristol-Myers Squibb to Focus Solely on Immunotherapy Oncology Treatments
Bristol-Myers Squibb Co in a report on Thursday, held that it would focus its efforts solely on cancer research.
Scientists Establish Use of Antihypertensive Drug to Fight Cocaine and Alcohol Addiction
In the first-of-its-kind research, scientists from the University of Texas at Austin have made interventions in controlling cocaine and alcohol addiction, by using an antihypertensive drug.
FDA Panel Approves Sanofi’s Cholesterol-Lowering Drug amid Reservations
Sanofi and Pharmaceuticals’ new cholesterol-lowering drug, Praluent, finally cleared the watchful eye of the US Food and Drug Administration, on Tuesday.
FDA To Decide on the Fate of Two New Cholesterol-Lowering Drugs
The much talked about new cholesterol-lowering drugs are being taken up for approval by the US Food and Drug Administration.
